Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Complicated Urinary Tract Infection: full-pipeline trial registry
1 of 2 indexed Complicated Urinary Tract Infection trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Complicated Urinary Tract Infection: 2 US clinical trials tracked, 1 recruiting.
Complicated Urinary Tract Infection is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC), running 1 of these trials.
Enrollment posture brief
Registry condition complicated-urinary-tract-infection
OPEN 1 | RECR 50% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Complicated Urinary Tract Infection lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Complicated Urinary Tract Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Complicated Urinary Tract Infection is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
NCT06672978
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
Pfizer
NCT01644643
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Complicated Urinary Tract Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Complicated Urinary Tract Infection trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Complicated Urinary Tract Infection page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Complicated Urinary Tract Infection trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) sponsors the most Complicated Urinary Tract Infection trials on record, review their full trial history before evaluating a specific study. See Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Complicated Urinary Tract Infection condition card totals 2 registered trials; most-linked intervention Best Available Therapy; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.